Bio-Techne Sustainability Profile
Bio-Techne Corporation, a leading player in the biotechnology sector, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1976, the company has established itself as a pioneer in providing high-quality reagents, instruments, and services for life sciences research and clinical diagnostics. Bio-Techne's core offerings include proteins, antibodies, and assay kits, which are distinguished by their exceptional quality and reliability. The company is renowned for its innovative solutions that support advancements in genomics, proteomics, and cell biology. With a strong market position, Bio-Techne has achieved notable milestones, including strategic acquisitions that have expanded its product portfolio and global reach, solidifying its reputation as a trusted partner in scientific research and development.
DitchCarbon Score
How does Bio-Techne's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bio-Techne's score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bio-Techne's reported carbon emissions
In 2024, Bio-Techne reported total greenhouse gas emissions of approximately 18,935,000 kg CO2e, encompassing both Scope 1 and Scope 2 emissions. This figure reflects a commitment to transparency in their environmental impact, with emissions from Scope 1 alone amounting to about 3,001,000 kg CO2e in 2023, while Scope 2 emissions (location-based) were approximately 14,565,000 kg CO2e for the same year. Bio-Techne has set ambitious climate commitments, having submitted a letter of commitment to reduce its Scope 1, 2, and 3 greenhouse gas emissions. This commitment is set to be validated by the Science Based Targets Initiative (SBTi) in 2026, indicating a proactive approach towards achieving significant reductions in their carbon footprint. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in the United States. As part of their sustainability strategy, Bio-Techne aims to enhance their emissions reporting and reduction initiatives, aligning with industry standards and expectations for corporate responsibility in climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 2,684,000 | 0,000,000 | 0,000,000 | - |
| Scope 2 | 12,694,000 | 00,000,000 | 00,000,000 | - |
| Scope 3 | - | - | - | - |
How Carbon Intensive is Bio-Techne's Industry?
How Carbon Intensive is Bio-Techne's Location?
Bio-Techne's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bio-Techne has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Bio-Techne's sustainability data and climate commitments